NORTHERN-DATA-AG
7.1.2021 09:41:26 CET | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87) acquires a data center facility in Northern Sweden to meet massive customer demand. The site currently consists of six data center halls on an area of 2.5 hectares and will now be further expanded by Northern Data following the acquisition.
Northern Data's new site is located in the Northern Swedish city of Boden, which has an average annual temperature of 1.3 degrees Celsius due to its location around 80 kilometers south of the Arctic Circle. The location is therefore ideal for passive energy-saving cooling of the HPC hardware.
In addition to the ideal HPC temperature conditions, the region in Northern Sweden is characterized by high connectivity and very cheap regional surplus electricity from renewable energy sources. The electricity for Northern Data's new site is 100 percent sourced from renewable energy, generated by hydropower plants in the region. The local hydropower plants have a capacity of about 4.5 gigawatts (GW), producing about 14 terawatt hours (TWh) per year, which is available to Northern Data at the lowest electricity prices in the EU.
Not least due to the cool air temperatures near the Arctic Circle, an excellent PUE value ("Power Usage Effectiveness") of 1.07 is achieved. The PUE value puts the total energy consumption of a data center in relation to the energy consumption of the IT infrastructure. The closer the value is to 1.0, the more efficient the data center. With a value of 1.07, Northern Data's future data center is among the worldwide leaders and is well below the industry average of 1.67.
The site, which has won awards for its ultra-efficiency, meets the very highest requirements, with various ISO certifications and was completed by data center operator Hydro66 only in 2019. Northern Data will start allocating hardware instantly due to the high demand from its customers and will continue to massively expand the site immediately.
Northern Data CEO Aroosh Thillainathan comments: "Due to the high demand for HPC capacity, we are constantly reviewing options to quickly secure additional sites through acquisitions in addition to building our own data centers. This allows us to further accelerate our growth. In view of this strategy, the new site in Northern Sweden is not only a real stroke of luck but also a significant expansion step for our company. Not only can we use it instantly, but we can also expand and develop it quite considerably, which we will do immediately. Our new site offers important advantages, such as lowest energy costs and ultra-efficiency, which will make it an important part of the Northern Data group going forward."
The acquisition of the entire data center facility, including two operating companies and part of the team, is still subject to, among others, a successful due diligence process and will take place through the issuance of EUR 21 million in shares, subject to a full lock-up period of two years, and a cash component of EUR 4 million.
About Northern Data:
Northern Data AG develops and operates global infrastructure solutions in the field of High Performance Computing (HPC). With its customized solutions, the company provides the infrastructure for diverse HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company is now a leading provider in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. In doing so, the company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. Northern Data currently employs around 150 people.
Disclaimer:
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG, nor does it constitute a securities prospectus of Northern Data AG. The information contained in this press release is not intended to be the basis for any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As in all business and investment matters, please consult qualified professional advice.
Language: |
English |
|
Company: |
Northern Data AG |
|
|
Thurn-und-Taxis-Platz 6 |
|
|
60313 Frankfurt/Main |
|
|
Germany |
|
Phone: |
+49 69 34 87 52 25 |
|
E-mail: |
||
Internet: |
||
ISIN: |
DE000A0SMU87 |
|
WKN: |
A0SMU8 |
|
Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg,
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005349/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
